Authors' response to a reply to ‘A phase II randomized controlled trial of nicotinamide for skin cancer chemoprevention in renal transplant recipients’

We thank Yelamos et al. for their interest in our nicotinamide chemoprevention studies.1 Some of their comments are pertinent, while others are based on a flawed interpretation of our data. Zhao2 previously commented on (nonsignificant) numerical differences in the frequency of adverse-event term groupings (mucocutaneous infections) between the placebo and nicotinamide groups in our ONTRAC chemoprevention study (Oral Nicotinamide To Reduce Actinic Cancer).3 As stated previously, chance remains a highly plausible explanation for the numerically higher mucocutaneous infections in the nicotinamide arm and also, for example, for the numerically lower respiratory infections observed in the nicotinamide arm.4 This article is protected by copyright. All rights reserved.